In CT26 and MC38 tumor models the PD-1Ab21 intraperitoneal administration revealed robust antitumoral effects compared to nontreated group and groups treated with anti-PD-1 antibody or mAb PD-1 plus IL-21 groups. Here, PDCD1 is linked to neoplasm.